| Trial Identifier: | 2074-CL-0101 |
| Sponsor: | Astellas Pharma Global Development Inc. |
| Start Date: | February 2023 |
| Primary Completion Date: | October 2024 |
| Study Completion Date: | October 2024 |
| Condition: | Cancer - Other |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| Country | Location |
|---|---|
| Japan, Aichi | Nagoya, Aichi, Japan |
| Japan, Chiba | Kashiwa, Chiba, Japan |
| Japan, Osaka | Osaka, Japan |
| Japan, Tokyo | Chuo-ku, Tokyo, Japan |
| Japan, Tokyo | Koto-ku, Tokyo, Japan |
| United States of America, CA | Sacramento, CA, United States of America, 95817 |
| United States of America, IA | Iowa City, IA, United States of America, 52242 |
| United States of America, MI | Detroit, MI, United States of America, 48201 |
| United States of America, MI | Grand Rapids, MI, United States of America, 49546 |
| United States of America, North Carolina | Durham, North Carolina, United States of America, 27710 |
| United States of America, RI | Providence, RI, United States of America, 02903 |
| United States of America, Texas | San Antonio, Texas, United States of America, 78229 |
| United States of America, WA | Seattle, WA, United States of America, 98101 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2026 Pharma Intelligence UK Limited (Citeline), a Norstella company